NCT00831649View on ClinicalTrials.gov

A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

PHASE2TerminatedINTERVENTIONAL
Timeline

Start Date

September 30, 2004

Primary Completion Date

February 28, 2005

Conditions
Rheumatoid Arthritis
Interventions
DRUG

natalizumab

Sponsors

Lead Sponsor

Biogen

Collaborators (1)

Elan Pharmaceuticals
All Listed Sponsors
collaborator

Elan Pharmaceuticals

INDUSTRY

lead

Biogen

INDUSTRY

NCT00831649 - A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201 | Biotech Hunter | Biotech Hunter